Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Decreases By 60.9%

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the recipient of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 32,380 shares, a decrease of 60.9% from the June 15th total of 82,735 shares. Based on an average daily volume of 64,916 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On OKYO Pharma

Several large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of OKYO Pharma in the fourth quarter worth $36,000. Finally, Citadel Advisors LLC purchased a new stake in shares of OKYO Pharma during the third quarter worth $31,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Stock Performance

Shares of OKYO Pharma stock traded up $0.03 during trading hours on Tuesday, hitting $1.58. The company’s stock had a trading volume of 35,192 shares, compared to its average volume of 166,447. OKYO Pharma has a twelve month low of $1.42 and a twelve month high of $3.35. The firm has a fifty day moving average of $1.61 and a 200-day moving average of $1.77.

Wall Street Analyst Weigh In

Several research firms have weighed in on OKYO. HC Wainwright decreased their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, OKYO Pharma presently has a consensus rating of “Hold” and a consensus price target of $5.67.

Key Stories Impacting OKYO Pharma

Here are the key news stories impacting OKYO Pharma this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on OKYO Pharma and maintained a $5.00 price target, even after lowering the target from $7.00. The firm’s updated earnings estimates suggest continued losses, but the bullish rating and higher-than-current valuation view may be supporting sentiment. Article: OKYO Pharma Ltd. PT Lowered to $5 at H.C. Wainwright
• Positive Sentiment: OKYO Pharma said it will highlight its neuropathic corneal pain program at the Piper Sandler Virtual Ophthalmology Symposium, which could keep investor attention on its clinical pipeline and potential catalysts. Article: OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
• Neutral Sentiment: HC Wainwright also published detailed EPS estimates for fiscal 2027 and 2028, pointing to ongoing losses but no major change in the company’s near-term earnings outlook. This is mostly a valuation update rather than a new fundamental development. Article: OKYO Pharma Limited Sponsored ADR
• Neutral Sentiment: News that OKYO Pharma’s short interest declined sharply could be supportive, but it is a secondary technical factor and less important than the analyst and pipeline headlines. Article: OKYO Pharma Sees Large Decline in Short Interest

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.